Epsilon M&A Deal Report - Retrogenix
Transaction Multiples for the Valuation of Private Companies
Charles River Discovery Research Services UK / Retrogenix
No EMAT :
114147
Announced Date :
31/03/2021
Type :
Acquisition of Majority Stake
Deal Value :
Yes
Acquirer :
Charles River Discovery Research Services UK
Target :
Retrogenix
Country :
England
Sector of activity :
- Laboratories > Pharmaceuticals & Cosmetics > Health, Pharmaceuticals & Biotechnology > Biomedical Research Laboratory
Business Description :
Retrogenix operates an early-stage contract research organisation (CRO) providing specialised bioanalytical services utilising its proprietary cell microarray technology. > Offers cell microarray...
Transaction multiples available
| EV/ Sales |
EV/ Gross Profit |
EV/ EBITDA |
EV/ EBIT |
Eq/ PBT |
P/E | Price to Book |
Specific multiple(s) |
|
|---|---|---|---|---|---|---|---|---|
| Historic | 
|
|
||||||
| Current |
|
Rating :
**
|
|
Multiple available |
| n.s. | Multiple calculated, but not significant |
Source: Epsilon Research / EMAT
Comparable Transactions
- Number of EMAT Reports / sub-sector « Biomedical Research Laboratory » = 32
| Date | Acquirer | Target | Country | Multiples | See details |
| 18/07/2023 | Groupe Vabel | Laboratoires Sarbec | Nord | * | 113988 |
| 24/04/2020 | Orifarm Group | Takeda Pharmaceutical's OTC and prescription pharmaceutical products in Europe | Europe | ** | 113870 |
Source: Epsilon Research / EMAT
